Gilead–The Predictable Path or the Road Less Traveled?

09-17-2014 Blog PostsPress Release

Gilead should be commended for taking action to make their best-selling treatment for Hepatitis C, Sovaldi, available to more people around the world. In India, they’ve struck licensing agreements with generic firms to produce the product for pennies on the dollar. Unfortunately, Gilead’s largess is being funded largely on the backs of American families.

Gilead Can Afford to Take These Three Steps to Lower the Price of Sovaldi

07-24-2014 Blog PostsPress Release

Yesterday’s blockbuster earnings announcement from Gilead underscores how much room the drug manufacturer has to lower the price of its Hepatitis C drug Sovaldi.  In fact, nearly all of Gilead’s profits came from its U.S. sales of Sovaldi. The $3.48 billion that Gilead earned from sales of Sovaldi in the second quarter is only going […]

[NCHC] Earnings Report Shows Gilead Can Lower Sovaldi’s Unsustainable Price

07-23-2014 Blog PostsPress Release

Statement from the National Coalition on Health Care’s President and CEO John Rother on the latest quarterly earnings report from Gilead Sciences, Inc., manufacturer of the hepatitis C drug Sovaldi:   “It’s clear Gilead has plenty of room to reduce the $1000 per pill price in order to ensure patients have access to this critical […]

[NCHC] Where is the Value in Overpricing Innovative Treatments?

07-17-2014 Press Release

At $1,000 per pill, the price of the new hepatitis C drug Sovaldi has generated much attention. It’s certainly a breakthrough drug and the type of innovation we want  – but it’s also priced at a level that prohibits access for millions of people and undercuts the very innovation and value for which Sovaldi is […]

[NCHC] AEI Session on Financing Cures: White Hat or White Wash?

07-10-2014 Press Release

On Friday, July 11, AEI is hosting a session entitled “How will we pay for the cost of cures?” On its face this seems like a laudatory endeavor.  After all, as a society we need to ensure we have adequate financing mechanisms for medical innovation.  However, there is a risk that the panelists avoid the […]

[NCHC] New York Joins List of States Outraged Over Sovaldi

06-30-2014 Press Release

Costs to New Yorkers for One Drug Is 4 Times Entire Higher Education Spending A recent article in Capital New York  highlights the dilemma posed by Gilead’s new Hepatitis C drug, Sovaldi.  While an important new therapy for patients the drug has been priced in such a way that it threatens to undermine the public […]

[] The fiercest debate in health care is about a $1,000 pill

05-28-2014 Press Release

“The people who pay for drugs aren’t fully buying those arguments — and want Sovaldi to back off its prices. They argue that Gilead could more than cover the costs of drug development and even run a profit with a lower price. This year alone, analysts expect Sovaldi to generate as much as $15 billion […]

[Kaiser Health News] ‘National Dialogue’ Urged On Cost Of New Hepatitis C Drug

05-28-2014 Press Release

“The outcry continues over the $1,000-a-pill hepatitis C drug made by California-based Gilead Sciences. While the drug is a significant advance over older treatments for the viral liver disease, the price set by the company ‘represents an abuse of market power,’ said John Rother, president and CEO of the National Coalition on Health Care, which […]


05-28-2014 Press Release

“A broad coalition of health care groups is trying to compel the pharmaceutical company Gilead to slim down its profits on the multibillion-dollar hepatitis drug. The “miracle” med costs about $84,000 for a 12-week treatment that effectively cures hepatitis C more than 90 percent of the time — far more effective than earlier drugs that […]

[POLITICO Pro] 80-group campaign targeting hepatitis drug cost

05-28-2014 MediaPress Release

“More than 80 organizations are launching the Campaign for Sustainable Rx Pricing to bring the pharmaceutical company Gilead to the table to negotiate a lower price, hoping that public pressure will prevail where private entreaties have not. John Rother, CEO of the National Coalition on Health Care, said Gilead’s pricing amounts to ‘an abuse of […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.